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Abstract
Background: About half of all prostate cancers harbor the TMPRSS2:ERG (T2E) gene fusion. While T2E-positive and
T2E-negative tumors represent specific molecular subtypes of prostate cancer (PCa), previous studies have not yet
comprehensively investigated how these tumor subtypes differ at the epigenetic level. We therefore investigated
epigenome-wide DNA methylation profiles of PCa stratified by T2E status.
Results: The study included 496 patients with clinically localized PCa who had a radical prostatectomy as primary
treatment for PCa. Fluorescence in situ hybridization (FISH) “break-apart” assays were used to determine tumor
T2E-fusion status, which showed that 266 patients (53.6 %) had T2E-positive PCa. The study showed global DNA
methylation differences between tumor subtypes. A large number of differentially methylated CpG sites were
identified (false-discovery rate [FDR] Q-value <0.00001; n = 27,876) and DNA methylation profiles accurately
distinguished between tumor T2E subgroups. A number of top-ranked differentially methylated CpGs in genes
(FDR Q-values ≤1.53E−29) were identified: C3orf14, CACNA1D, GREM1, KLK10, NT5C, PDE4D, RAB40C, SEPT9, and TRIB2,
several of which had a corresponding alteration in mRNA expression. These genes may have various roles in the
pathogenesis of PCa, and the calcium-channel gene CACNA1D is a known ERG-target. Analysis of The Cancer
Genome Atlas (TCGA) data provided confirmatory evidence for our findings.
Conclusions: This study identified substantial differences in DNA methylation profiles of T2E-positive and
T2E-negative tumors, thereby providing further evidence that different underlying oncogenic pathways characterize
these molecular subtypes.
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Background
In 2005, Tomlins et al. identified the fusion of two genes,
ERG and TMPRSS2, as a common somatic alteration in
prostate cancer (PCa) [1]. Formation of the TMPRSS2:ERG
(T2E) gene fusion results in overexpression of ERG, a
known oncogene and member of the ETS transcription
factor family [1]. TMPRSS2 is an androgen-regulated gene
that encodes a serine protease and is preferentially
expressed in the prostate [2]. The gene fusion can result
from a chromosomal translocation or interstitial deletion
[3]. About 50 % of PCa patients of European ancestry har-
bor T2E-positive tumors, but lower frequencies have been
reported in men of African or Asian ancestry [4]. The T2E
gene fusion is an early event in PCa, and fusion-positive tu-
mors are believed to represent a distinct molecular subtype
of PCa involving activation of specific oncogenic pathways
[2, 3, 5–13].
The gene fusion may have clinical implications. It has
been shown that the T2E transcript can be detected in
urine and that this represents a specific biomarker for
the detection of PCa [14]. Several studies have also in-
vestigated fusion status in relation to PCa outcomes, but
a recent meta-analysis of 48 studies showed no evidence
of an association with recurrence-free or disease-specific
survival [15]. Although the clinical relevance of molecu-
lar subtyping of PCa by T2E status is unknown, it might
allow patient stratification for different management
strategies [16, 17].
DNA methylation of cytosines in CpG dinucleotides is
an epigenetic mechanism for control of gene transcrip-
tion [18, 19]. CpG sites are commonly found in clusters
called CpG islands, which are often in gene promoter re-
gions. While CpGs outside islands are usually methyl-
ated, CpGs in islands in gene promoter regions are
typically unmethylated [18]. Hypermethylation of gene
promoter regions can lead to transcriptional silencing,
but DNA methylation changes outside gene promoter
regions (e.g., the gene body) can also play critical roles
in the regulation of gene activity and genomic stability
[20, 21]. Both losses and gains of DNA methylation have
been associated with cancer, including PCa [18, 22].
There is preliminary evidence from two small studies
that T2E status is associated with changes in DNA methy-
lation [23, 24]. Both studies used an epigenome-wide ap-
proach that focused on larger differentially methylated
regions (≥500 bp). Using this approach, many key
(de)methylated CpG sites that are critical for regulating
gene expression may have been missed [25]. Further re-
search is therefore needed to precisely assess DNA methy-
lation at single CpG resolution in fusion-positive versus
fusion-negative prostate tumors. Another limitation of
these previous analyses is the small sample size. The total
number of fusion-positive and fusion-negative tumors in
the first and second study was 9 and 37, respectively.
The present study investigated epigenome-wide DNA
methylation profiles in T2E-fusion-positive versus T2E-
fusion-negative prostate tumors in a large population-
based cohort of 496 patients to identify differentially
methylated CpG sites. We integrated methylation results
with gene expression data, from the same patients’
tumor samples, to investigate the potential effects of dif-
ferential DNA methylation on mRNA expression levels.
Further, data from The Cancer Genome Atlas (TCGA)
were used to independently validate our methylation
findings.
Results
The study included 496 PCa patients who received radical
prostatectomy as primary treatment for clinically localized
disease. Of these, 266 (53.6 %) were T2E-fusion-positive
(Table 1). Fusion-positive PCa was associated with youn-
ger ages at cancer diagnosis, European-American race,
and lower Gleason scores.
A principal component analysis of DNA methylation
levels was conducted. The 5000 most variable CpG sites
in the dataset were used as input for this analysis. In a
plot of principal component 1 vs. 2, T2E-positive and
T2E-negative tumors were separated, suggesting that
these tumor subtypes have a distinct DNA methy-
lome (Fig. 1a). After that, we calculated the average
DNA methylation level of the 5000 most variable CpG
sites in T2E-positive and T2E-negative PCa, stratified by
genetic location. This showed that DNA methylation
levels were higher in T2E-positive tumors (P value <0.05;
Fig. 1b).
Figure 2a shows a Manhattan plot, which highlights the
distribution of differentially methylated CpG sites across
the genome. There were 27,946 differentially methylated
CpGs (false-discovery rate [FDR] Q-value <0.00001), in-
cluding 19,281 CpGs (69 %) that were hypermethylated
and 8595 CpGs (31 %) that were hypomethylated in
fusion-positive versus fusion-negative PCa. Figure 2b
shows the frequency of all evaluated and the significantly
hyper- and hypomethylated CpG sites by genetic location.
Similarly, Fig. 2c shows these frequencies by epigenetic
location. These figures illustrate that the frequencies of
hyper- and hypomethylated CpGs in many gene and
epigenetic locations differ from the frequencies of all
evaluated CpGs in these locations. In particular, hyper-
methylated CpGs were enriched in intergenic and open
sea regions but underrepresented in CpG islands and
promoter regions.
Of the 27K significant CpG sites, 3103 had a mean
methylation difference of at least 10 % between T2E sub-
types (Additional file 1). Figure 3 shows a heat map of
these 3K CpGs based on supervised clustering. This
again shows that fusion-positive and fusion-negative
prostate tumors have distinct epigenetic profiles. These
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differentially methylated CpG sites involved 1962 genes.
This set of genes was used for gene ontology (GO) ana-
lysis. We found that seven of the top ten identified GO-
associated biological pathways were related to develop-
mental processes (not shown).
Next, we focused on the differentially methylated CpGs
with the largest mean methylation difference between fu-
sion-negative and fusion-positive PCa (≥25 %). Twenty-
five such top-ranked CpGs were identified (Fig. 4a,
Table 2), of which 19 were hypermethylated and six
Fig. 1 DNA methylation and T2E status. a Principal component (PC) analysis plot based on the 5000 most variable CpG sites in the dataset. b
Average DNA methylation level of the same 5000 CpG sites, by genetic location (Illumina annotation). Statistically significant differences are
highlighted; *P value <0.05, **<0.01, or ***<0.001
Table 1 Characteristics of PCa patients by T2E-fusion status
T2E-negative PCa (n = 230) T2E-positive PCa (n = 266)
Variables No. % Mean (SD) No. % Mean (SD) P valuea
Age at diagnosis (years) – – 59.5 (7.1) – – 56.8 (6.8) <0.01
Race <0.01
African-American 29 12.6 – 14 5.3 – –
European-American 201 87.4 – 252 94.7 – –
Gleason score <0.01
≤6 92 40.0 – 141 53.0 – –
7 (3 + 4) 89 38.7 – 93 35.0 – –
7 (4 + 3) 29 12.6 – 15 5.6 – –
≥8 20 8.7 – 17 6.4 – –
Pathological stage 0.70
Local (pT1/pT2) 159 69.1 – 179 67.3 – –
Regional (pT3) 71 30.9 – 87 32.7 – –
PSA (ng/mL) at diagnosis 0.06
<4 26 12.0 – 52 20.6 – –
4– < 10 138 63.6 – 156 61.9 – –
10– < 20 38 17.5 – 28 11.1 – –
≥20 15 6.9 – 16 6.3 – –
T2E TMPRSS2:ERG, PCa prostate cancer, SD standard deviation, PSA prostate-specific antigen
aA t test (age at diagnosis) or chi-square test (all categorical variables) was used
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were hypomethylated in fusion-positive versus fusion-
negative PCa. Fifteen of the hypermethylated CpGs
were in six genes: PDE4D (n = 6), SEPT9 (n = 3), NT5C
(n = 2), C3orf14 (n = 2), KLK10 (n = 1), and TRIB2 (n =
1); all six hypomethylated CpGs were in three genes:
CACNA1D (n = 4), RAB40C (n = 1), and GREM1 (n =
1). Four hypermethylated CpGs were intergenic including
one CpG on chromosome 12 and three CpGs on
chromosome 17. Three of the 25 CpGs were in single
nucleotide polymorphism (SNP) loci: PDE4D
cg22706610, cg13468945, and GREM1 cg17312492, and
the associations of these specific CpGs therefore need
to be interpreted with caution.
DNA methylation at adjacent CpG sites is typically
correlated. Correlations between the methylation levels
of the CpG sites in Table 2 that were in the same gene
(i.e., PDE4D, SEPT9, NT5C, C3orf14, and CACNA1D)
were ≥0.9. The three intergenic CpGs on chromosome
17 (Table 2) were in the same 803-bp region, and methy-
lation levels of these CpGs were also highly correlated
(r2 ≥ 1.0). Further, all 25 top CpGs were in larger differ-
entially methylated regions that included multiple add-
itional CpG sites for which DNA methylation levels
were correlated (r2 ≥ 0.8; median number of CpGs per
region = 5, range 2–10).
A hierarchical clustering analysis based on the methy-
lation levels of the 25 top-ranked CpGs identified two
main clusters, one that consisted primarily of fusion-
positive tumors (89 %) and the other that consisted
mostly of fusion-negative tumors (87 %; Fig. 4b). These
data suggest that epigenetic profiles based on these 25
CpG sites can separate fusion-positive from fusion-
negative prostate tumors.
Next, we investigated the associations between T2E
status and methylation of the 25 top CpGs in subgroups
of European-American (n = 453) and African-American
Fig. 2 Differentially methylated CpG sites in fusion-positive versus fusion-negative PCa. a Manhattan plot of DNA methylation. The horizontal axis
shows the chromosomes. A 10,000-bp “gap” was added between each chromosome to aid visualization. The dashed line represents the P value
that corresponds to the FDR Q-value threshold for statistical significance of 0.00001. In total, 19,281 hypermethylated and 8595 hypomethylated
CpGs reached statistical significance. The frequency of all evaluated and hyper- and hypomethylated CpG sites by b gene region and c epigenetic
region. Genetic and epigenetic locations are based on Illumina annotation. Statistically significant differences are highlighted; *P value <0.05,
**<0.01, or ***<0.001
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patients (n = 43). Although the analysis of African-
American men was underpowered, all associations were
in the same direction in both subgroups, suggesting that
these associations are not substantially different for these
two ancestry groups. In addition, associations between
fusion status and DNA methylation of the 25 top-ranked
CpGs were investigated in subgroups based on Gleason
score (≤7 [3 + 4] vs. ≥7 [4 + 3]) and age at diagnosis (<60
vs. ≥60 years), which showed no substantial differences.
mRNA expression levels of the nine genes containing
the top-ranked differentially methylated CpGs (Table 2)
were investigated using the same patients’ tumor tissue
samples. Methylation levels of CpG sites in six of these
genes were correlated with gene expression levels (P
value <0.05): C3orf14 (range r2 −0.60, −0.63), CAC-
NA1D (range r2 −0.39, −0.45), GREM1 (r2 −0.32),
NT5C (r2 −0.42), SEPT9 (range r2 0.24, 0.31), and
TRIB2 (r2 −0.24). In addition, the expression of ERG
was investigated and we confirmed its overexpression
in fusion-positive compared to fusion-negative PCa
(log2 fold change = 1.92, P value = 1.82E−68).
In a final analysis, we aimed to confirm our methylation
findings in The Cancer Genome Atlas (TCGA) dataset.
Because T2E-fusion status was not directly determined in
TCGA using fluorescence in situ hybridization (FISH), we
used ERG mRNA overexpression as a proxy for positive
fusion status, as described previously [26–28]. As such, we
found that 187 of the 468 TCGA prostate tumor samples
available for analysis were T2E-fusion-positive (40 %).
First, we focused on all 27K significant CpG sites in our
study. This showed that the majority of hyper- (91 %) and
hypomethylated (98 %) CpGs in our study, with available
methylation data in TCGA, were similarly associated with
fusion status in TCGA (P value <0.05). Second, the 25
top-ranked CpGs in our study were examined in more de-
tail. Methylation data were available for 24 of the 25
CpGs; GREM1 cg17312492 was not available in the TCGA
dataset. The 24 CpGs were similarly differentially methyl-
ated by T2E status in TCGA (P values ≤5.44E−37); mean
methylation differences between patient groups for these
CpGs ranged from 24 to 49 % (mean = 36 %). Similarly as
in our discovery cohort, hierarchical clustering using the
methylation levels of these CpGs identified two main clus-
ters, one that consisted primarily of fusion-positive tumors
(89 %) and the other that consisted mostly of fusion-
negative tumors (95 %; Fig. 4c). Our demonstration of
these results across two cohorts suggests that these top
differentially methylated CpGs and genes are strongly and
robustly associated with T2E status.
Discussion
The present study identified substantial DNA methylation
differences in T2E-positive and T2E-negative prostate tu-
mors. We found global DNA methylation differences and
identified a large number of differentially methylated CpG
sites. Fusion-positive and fusion-negative prostate tumors
could be accurately distinguished by their DNA methyla-
tion profiles. Several of the top-ranked genes identified in
Fig. 3 Heat map of DNA methylation M-values in fusion-positive versus fusion-negative PCa, based on supervised clustering. The columns represent
the prostate tumor samples (fusion-positive is shown under the red bar and fusion-negative is shown under the green bar). The heat map includes
3101 differentially methylated CpG sites (T2E+ vs. T2E─) with FDR Q-value <0.00001 and a mean methylation difference of at least 10 % between tumor
types (rows). Higher methylation levels are shown in red and lower methylation levels are shown in blue (white is intermediate)
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this study showed aberrant DNA methylation levels that
correlated with altered mRNA expression levels, suggest-
ing a role for DNA methylation in regulating the tran-
scription of these genes. Analysis of TCGA data provided
confirmatory evidence for our findings.
A number of previous studies found that CACNA1D
expression correlates with ERG overexpression in T2E-
fusion-positive PCa, suggesting that CACNA1D is an
ERG target gene [5, 7–13]. CACNA1D is a calcium-
channel gene that encodes the L-type calcium-channel
alpha 1D subunit (Cav1.3), which is involved in several
biological processes including cell signaling and calcium
homeostasis [29, 30]. This epigenome-wide analysis of
fusion-positive versus fusion-negative PCa identified
Fig. 4 Twenty-five top-ranked differentially methylated CpG sites in fusion-positive versus fusion-negative PCa. a Volcano plot of DNA methylation.
Differentially methylated CpGs (FDR Q-value <0.00001; n = 27,946) are displayed in green or red. The 25 red-labeled CpGs had a mean methylation
difference of at least 25 % between tumor types, and the figure shows the genes these CpG sites map to. Four of the 25 CpGs were intergenic. b
Unsupervised clustering using the 25 top differentially methylated CpG sites (rows) with FDR Q-value <0.00001 and a mean methylation difference of
at least 25 % between prostate tumor types, in our cohort. The columns represent the prostate tumor samples (fusion-positive is shown under
the red bar and fusion-negative is shown under the green bar). Higher methylation levels are displayed in red and lower methylation levels are
shown in blue (white is intermediate). Two main clusters were identified, one that consisted primarily of fusion-positive tumors (89 %) and the
other that consisted mostly of fusion-negative tumors (87 %). c Unsupervised clustering using the top CpG sites in TCGA (same approach as in
b). One of the CpG sites (GREM1 cg17312492) was not represented in TCGA data, and the analysis therefore only included 24 CpG sites. Similar to our
results, clustering using these CpG sites clearly separated fusion-positive from fusion-negative PCa. One of the two clusters contained 89 % of
fusion-positive tumors and the other cluster contained 95 % of fusion-negative tumors
Geybels et al. Clinical Epigenetics  (2015) 7:128 Page 6 of 12
Table 2 Top-ranked differentially methylated CpGs in T2E-fusion-positive versus T2E-fusion-negative prostate tumors
CpG ID Chromosome Gene Location CpG island Mean β T2E-negative Mean β T2E-positive Mean β difference Q-value
Hypermethylation
cg11258089 5 PDE4D Body; TSS200 Yes 0.20 0.53 0.33 1.19E−51
cg22706610 5 PDE4D Body; TSS200 Yes 0.22 0.50 0.28 1.19E−51
cg26870744 5 PDE4D Body; TSS200 Yes 0.17 0.43 0.27 1.19E−51
cg07190535 5 PDE4D Body; TSS1500 Yes 0.26 0.53 0.27 1.57E−50
cg08554295 5 PDE4D Body; TSS1500 No 0.18 0.46 0.29 1.57E−50
cg16261871 5 PDE4D Body; TSS200 Yes 0.25 0.52 0.28 2.83E−46
cg19694010 12 – IGR Yes 0.19 0.45 0.27 3.45E−46
cg15044248 17 SEPT9 TSS200; 5′ UTR; body Yes 0.11 0.38 0.26 7.05E−46
cg14087806 17 – IGR Yes 0.19 0.49 0.30 7.05E−46
cg06848185 17 SEPT9 TSS1500; 5′ UTR; body Yes 0.10 0.36 0.26 3.84E−45
cg13468945 17 – IGR Yes 0.19 0.47 0.29 4.20E−43
cg08378505 17 NT5C Body Yes 0.15 0.45 0.30 3.41E−40
cg17300544 17 SEPT9 TSS200; 5′ UTR; body Yes 0.18 0.47 0.29 7.49E−39
cg26896572 3 C3orf14 TSS1500 Yes 0.26 0.53 0.27 2.28E−38
cg21454031 17 – IGR No 0.22 0.48 0.26 5.03E−38
cg10520594 17 NT5C Body Yes 0.19 0.44 0.25 9.43E−38
cg15059608 3 C3orf14 TSS1500 No 0.32 0.58 0.25 3.36E−31
cg21869055 19 KLK10 5′ UTR Yes 0.26 0.51 0.25 3.06E−30
cg25623934 2 TRIB2 Exon 1; body Yes 0.22 0.49 0.27 1.53E−29
Hypomethylation
cg08480458 3 CACNA1D Body Yes 0.47 0.15 0.32 5.42E−45
cg15473186 3 CACNA1D Body Yes 0.57 0.31 0.27 1.28E−44
cg06717750 16 RAB40C Body No 0.80 0.52 0.28 6.87E−43
cg12668309 3 CACNA1D Body Yes 0.33 0.08 0.26 4.18E−42
cg17312492 15 GREM1 5′ UTR Yes 0.43 0.17 0.26 7.96E−42
cg14337339 3 CACNA1D Body Yes 0.43 0.12 0.31 3.41E−40
The table shows differentially methylated CpGs (FDR Q-value <0.00001) that have a mean methylation (β-value) difference of at least 25 % between fusion-positive versus fusion-negative PCa










CACNA1D as one of nine top-ranked differentially meth-
ylated genes and confirmed that the gene transcript is
overexpressed in fusion-positive PCa. A CpG island in the
gene body of this gene had lower methylation levels in
fusion-positive than fusion-negative PCa. Interestingly, a
previous study of DNA methylation in fusion-positive
(n = 17) versus fusion-negative PCa (n = 20) found two
larger hypomethylated regions, 500 bp in size, that were
in the same genomic region as the hypomethylated
CpG sites in the gene body of CACNA1D identified in
the present study [23].
While promoter hypermethylation is often associated
with transcriptional repression, less is known about the bio-
logical consequences of differential DNA methylation out-
side gene promoter regions [21]. Increasing evidence,
however, suggests that differential methylation in gene
body regions may also play critical roles in gene regulation
[20, 21]. Gene body methylation has been both positively
and inversely associated with mRNA expression, and the
direction of the effect may depend on the location of the ab-
errantly methylated CpG sites in the gene body [20, 21, 31].
The present study, therefore, supports a role forCACNA1D
in PCa and provides evidence suggesting that overexpres-
sion of CACNA1D in T2E-positive tumors may result from
hypomethylation of a CpG island in the gene body. These
findings may have consequences for the treatment of PCa.
In particular, there is some recent evidence suggesting that
CACNA1D overexpression may induce prostate carcino-
genesis and that these cancer-promoting effects may be
counteracted by inhibition of the gene or the protein it
encodes [7]. Further, a number of other recent studies
provided evidence for a link between aberrant calcium-
channel functioning and PCa [32–34].
The two other top-ranked hypomethylated CpGs in
this study were in the gene body of RAB40C and the 5′
UTR of GREM1. While RAB40C methylation was not
correlated with gene expression, GREM1 showed higher
mRNA transcript levels in fusion-positive PCa as com-
pared to fusion-negative PCa. GREM1 encodes a mem-
ber of the bone morphogenic protein antagonist family
[35]. RAB40C is a member of the RAS oncogene family,
but the gene has not been well characterized [36].
The 19 hypermethylated CpGs in fusion-positive versus
fusion-negative PCa included 15 CpGs in six genes:
PDE4D, SEPT9, NT5C, C3orf14, KLK10, and TRIB2; and
four intergenic CpGs including three CpGs near each
other on chromosome 17. Six hypermethylated CpGs were
in PDE4D (gene body or transcription start site). These
CpGs were in or near the same CpG island, and their
methylation levels were correlated. Phosphodiesterase 4D
(PDE4D) may induce PCa cell proliferation [37], and one
recent study showed that PDE4D inhibitors reduce pros-
tate tumor growth in animal models [38]. Phosphodiester-
ases play important roles in cellular signaling [38].
SEPT9 is a member of the septin family [39]. In the
present study, SEPT9 was associated with hypermethylation
(promoter and gene body region) in fusion-positive PCa as
compared to fusion-negative tumors, and gene expression
was also higher in fusion-positive cases. While promoter
hypermethylation is typically associated with transcrip-
tional repression, a number of mechanisms via which
gene body methylation changes may increase transcrip-
tional activity have been suggested including blocking
the initiation of intragenic promoters and affecting the
activity of repetitive DNA elements within the tran-
scriptional unit [31]. In a previous analysis, our group
showed SEPT9 hypermethylation in PCa compared to
adjacent benign prostate tissue [40]. Furthermore, pre-
vious studies have identified hypermethylation of the
SEPT9 promoter region as a common event in a num-
ber of other cancers, and a diagnostic test that mea-
sures SEPT9 methylation levels has been developed for
colorectal cancer [41]. This study also showed pro-
moter hypermethylation of KLK10 and TRIB2, and
TRIB2 transcript levels were lower in T2E-positive PCa.
KLK10 is a member of the kallikrein family, which also
includes KLK3, the gene that encodes prostate-specific
antigen (PSA) [42]. A recent study showed that CpG
methylation of KLK10 was higher in prostate tumor
compared to normal tissue and also reported an associ-
ation between DNA methylation and clinicopathologi-
cal parameters [43]. TRIB2 plays a role in signal
transduction pathways [44].
The gene C3orf14 exhibited both promoter region
hypermethylation and a corresponding strong decrease
in mRNA expression. Although the function of this gene
is unknown, a previous genome-wide analysis of glio-
blastoma versus normal brain tissue showed an inverse
correlation between promoter region CpG methylation
and mRNA expression of C3orf14 [45].
Lastly, the gene NTC5 had gene body hypermethyla-
tion and a decrease in mRNA expression. This gene en-
codes an enzyme that is critical for the physiological
control of energy balance, metabolic regulation, and cell
replication [46]. In summary, several of the top-ranked
differentially methylated genes in the present study have
molecular functions that suggest they may play a role in
PCa. Further studies are needed to understand the spe-
cific mechanisms that underlie the link between differen-
tial DNA methylation and altered mRNA expression in
these genes and prostate carcinogenesis.
Strengths of our study include the relatively large sam-
ple size, the epigenome-wide approach to identify differ-
entially methylated CpG sites, and the ability to stratify
patients by tumor T2E status as determined by FISH,
which is considered the “gold standard” for measuring
the gene fusion [47]. In addition, gene expression data
from the same patients’ tumors were available to
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evaluate the potential biological effects of aberrant DNA
methylation. We also used TCGA data to confirm our
methylation findings. One potential limitation of this
analysis is that T2E status was not directly measured
using FISH in TCGA. We therefore used ERG mRNA
expression to predict fusion status, and this indirect ap-
proach might have resulted in some misclassification.
However, previous studies showed high concordance
with T2E status as assessed by FISH and ERG mRNA ex-
pression [26–28]. Further, although we confirmed that
our top results were similar in subgroups of European
and African ancestry patients, the analysis of African-
American men may have been underpowered due to
small sample size.
Conclusions
We report significant changes in the DNA methylome of
T2E-positive versus T2E-negative prostate tumors. DNA
methylation profiles were able to accurately distinguish
between these major PCa subtypes. Results from our
study were independently validated in TCGA. Several of
the top-ranked differentially methylated genes in our
study also showed mRNA expression changes, thereby
providing evidence of an effect of aberrant DNA methy-
lation on gene expression. These genes may play an im-
portant role in prostate carcinogenesis and highlight
novel therapeutic targets that are specific for fusion-
positive PCa. The findings from this study show that
fusion-positive and fusion-negative PCa are epigeneti-
cally distinct, thereby providing further evidence that
these unique molecular subtypes involve distinct alter-
ations in disease pathways.
Methods
Prostate cancer patients
Data and tumor tissue samples were available from a co-
hort of patients who had radical prostatectomy as pri-
mary treatment for clinically localized PCa and who
participated in one of two prior population-based studies
[48, 49]. Baseline patient data were collected using an
in-person interview. Information on clinicopathological
parameters (e.g., Gleason score, disease stage, diagnostic
prostate-specific antigen (PSA) level) was obtained from
the Seattle-Puget Sound Surveillance, Epidemiology, and
End Results (SEER) cancer registry. All patients signed
informed consent, and procedures were approved by the
Institutional Review Board of the Fred Hutchinson Can-
cer Research Center (Seattle, WA).
Sample preparation
Formalin-fixed, paraffin-embedded (FFPE) blocks from
radical prostatectomy specimens were used to make
hematoxylin and eosin (H&E)-stained slides, which
were reviewed by a PCa pathologist to confirm the
presence and location of PCa within the blocks. Areas
containing ≥75 % cancer cells had two 1-mm tumor tis-
sue cores taken for DNA extraction, two for RNA ex-
traction and two for tissue microarray (TMA) and
immunohistochemistry analysis. In addition, for 20 pa-
tients (13 T2E-positive and 7 T2E-negative), adjacent non-
tumor (histologically benign) prostate tissue cores were
taken using the same procedure, and these samples were
used for epigenome-wide DNA methylation profiling. Ex-
traction of tumor DNA from the cores was completed
using the RecoverAll Total Nucleic Acid Isolation Kit
(Ambion/Applied Biosciences, Waltham, MA). The stand-
ard manufacturer’s protocol was followed, except that the
elution step was performed twice to maximize DNA yield.
Purified DNA was quantified (PicoGreen). RNA was iso-
lated using the RNeasy® FFPE Kit (Qiagen Inc., Valencia,
CA) and quantified using RiboGreen. DNA and RNA
samples were stored at −80 °C and shipped to Illumina,
Inc. (San Diego, CA) for completion of assays.
DNA methylation arrays
Samples were bisulfite-converted using the EZ DNA
Methylation Kit (Zymo Research, Irvine, CA) according
to the manufacturer’s protocol. Controls on the array were
used to track the bisulfite conversion efficiency. The Infi-
nium HumanMethylation450 (HM450) BeadChip array
(Illumina, Inc.) was used to measure epigenome-wide
DNA methylation using beads with target-specific probes
designed to interrogate individual CpGs (n >480,000) on
bisulfite-converted genomic DNA. Duplicate samples for
16 patients were used, and these samples were randomly
assigned to different plates. In addition, replicate tumor
DNA samples from two patients were placed on every
plate. All plates also contained Illumina controls and two
negative controls. Laboratory personnel were blinded to
patient characteristics (e.g.,T2E status) as well as to the lo-
cation of duplicate and replicate samples on plates. Sam-
ples were excluded if less than 95 % of the CpGs on the
array for that sample were detected with a detection P
value <0.05, which resulted in the exclusion of 33 sam-
ples (5.9 %). In total, 523 patients had available DNA
methylation data. Correlations between blind duplicates
ranged from 0.96 to 0.99 and were >0.99 for replicates
across plates.
Gene expression arrays
Expression profiling was done at Illumina using the
Whole-Genome DASL® (cDNA-mediated Annealing, Se-
lection, Extension, and Ligation) HT Assay (Illumina,
Inc.). Blind duplicate samples for six patients were ran-
domly distributed across plates. Four samples failed,
leaving 501 patients with available gene expression data.
Transcript correlations between duplicated samples
ranged from 0.96 to 0.99. In addition, replicate tumor
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RNA samples from two patients were included on every
plate, and the transcript correlations across plates were
0.95 for each subject.
Determination of TMPRSS2:ERG fusion status
Fluorescence in situ hybridization “break-apart” assays
were used to determine T2E-fusion status [50]. A two-
color fluorescence in situ hybridization technique was
used, and the green fluorescein isothiocyanate signals
were amplified with goat anti-fluorescein isothiocyanate
Fluorescein/Oregon Green Antibody, Alexa Fluor 488
conjugate (Life Technologies, Waltham, MA) antibodies.
Pictures were made with a Zeiss Axioplan 2 imaging sys-
tem (Carl Zeiss AG) using Metafer (MetaSystems Inc.,
North Royalton, OH) imaging software. A 4′,6-diami-
dino-2-phenylindole prescan (×10 magnification) of the
whole tumor tissue microarray slide was used to identify
the core positions. Core identification numbers were
assigned using a tumor tissue microarray tool imple-
mented in Metafer. Each core was scanned at ×40 mag-
nification, in a 6 × 9 grid of 54 fields. Each field was
photographed in at least three different focus planes
with filters for fluorescein isothiocyanate and cyanine 3.
Referring layer and filter captures were then merged into
one final three-colored image per field. Each core was
evaluated by two separate individuals to determine
whether the specimen was fusion-positive or fusion-
negative. If there was disagreement, the specimen was
reviewed until consensus was reached. Forty-eight
(7.9 %) cases were excluded because cores could not be
evaluated. Cores were considered positive if multiple
cells contained the T2E rearrangement. For 38 (6.7 %)
cases, T2E status had been determined using fluores-
cence in situ hybridization for a prior analysis [51], and
these data were included. In total, 496 patients had both
T2E-fusion status determined and DNA methylation
data, and 467 patients had both T2E status determined
and gene expression data.
The Cancer Genome Atlas prostate cancer data
Data from The Cancer Genome Atlas (TCGA) were
used to verify the most significant methylation results.
HM450 data (level 3) were downloaded from the TCGA
data portal (https://tcga-data.nci.nih.gov/tcga/). T2E sta-
tus was not directly measured in TCGA, but previous
studies have shown that ERG mRNA overexpression is
an accurate predictor of positive fusion status [26–28].
We therefore analyzed TCGA PCa (exon) expression
data (Illumina HiSeq; log2-normalized), which were down-
loaded from the UCSC (University of California, Santa
Cruz) Cancer Browser (https://genome-cancer.ucsc.edu/).
The mean ERG expression level across all samples was
2.12 (standard deviation = 1.48), and samples with an ERG
expression level higher than this mean value were
classified as tumors with ERG overexpression. Visual in-
spection of the data showed that this mean level is an ap-
propriate cut-point to identify tumors with ERG
overexpression. Of the 468 total samples available for
DNA methylation analysis, 187 showed ERG overexpres-
sion (40 %).
The TCGA cohort is not population-based but in-
cludes patients from at least 30 centers around the world.
High Gleason grade tumors are overrepresented in TCGA.
The number of patients with Gleason score ≤6, 7 (3 + 4), 7
(4 + 3), and ≥8 were 47 (10 %), 139 (30 %), 98 (21 %), and
184 (39 %), respectively. The Gleason score was not differ-
ent between tumors with versus without ERG overexpres-
sion (P value >0.05).
Data processing and statistical data analysis
The Bioconductor minfi package was used to analyze
the HM450 data. CpGs with an average detection P
value >0.01 (n = 3715) and non-CpG probes (n = 2799)
were excluded, and 478,998 CpGs were available for
analysis. The data were normalized using subset-quantile
within array normalization (SWAN) [52], and potential
batch effects were removed using ComBat [53]. Methyla-
tion β-values were calculated, which represent the methy-
lation level at each CpG locus: [intensity of the methylated
allele/(intensity of the unmethylated allele + intensity of
the methylated allele + 100)]. β-values range from 0
(unmethylated) to 1 (100 % methylated) and were used to
identify the mean percentage methylation difference be-
tween fusion-positive and fusion-negative PCa. Global
methylation levels were calculated by taking the average
methylation level across CpGs per genetic and epigenetic
location. Methylation M-values were also calculated by
taking the logit transformation of the β-values.
Linear regression (Bioconductor limma package) with
an empirical Bayes approach and using methylation M-
values was conducted to assess whether CpGs were as-
sociated with T2E-fusion status. Models were adjusted
for age at diagnosis (years; continuous), race (African-
American, European-American), Gleason score (≤6, 7
[3 + 4], 7 [4 + 3], ≥8), and study (study I, study II). The
same approach was used to analyze the gene expression
data. Linear models, adjusted for the same variables,
were also used to detect global DNA methylation differ-
ences. Statistical models used to analyze TCGA data
were adjusted for age and Gleason score but not race
because of missing data. False-discovery rate (FDR) Q-
values were calculated to control the proportion of false
positives, and a Q-value of less than 0.00001 was con-
sidered statistically significant. A chi-square test was
used to test whether the frequencies of evaluated,
hypermethylated, and hypomethylated CpG sites by
genetic and epigenetic locations were different. In sec-
ondary analyses, associations of the top-ranked CpGs
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with T2E status were studied in subgroups based on
race, Gleason score, and age at diagnosis. In addition,
associations between the top-ranked CpGs and Gleason
score (≥8 vs. ≤6) were studied in subgroups defined by
fusion status.
Annotation data for the HM450 array were used. A
gene promoter region was defined as follows: TSS1500,
TSS200, 5′ UTR, and exon 1. Manhattan and volcano
plots and heat maps were constructed to visualize the
data. Principal component analysis (prcomp) and clus-
tering (heatmap.2 in Bioconductor gplots package) were
also used to examine DNA methylation profiles. Methy-
lation M-values were input for these analyses. Gene
ontology analysis was conducted using hypergeometric
testing and the Bioconductor GOstats package. All
statistical analyses were conducted using the R
programming language (http://cran.r-project.org/) and
Bioconductor packages (http://bioconductor.org/).
Additional file
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